"country","first_author","source_name","estimate_grade","source_type","state","city","study_inclusion_criteria","study_exclusion_criteria","sex","sampling_start_date","sampling_end_date","population_group","age","denominator_value","serum_pos_prevalence","seroprev_95_ci_lower","seroprev_95_ci_upper","sampling_method","test_name","test_manufacturer","test_type","isotypes","antibody_target","test_validation","sensitivity","specificity","url","remarks"
"Cameroon","Karl Njuwa Fai","Serologic Response to SARS-CoV-2 in an African Population.","Regional","Journal Article (Peer-Reviewed)",NA,NA,"Individuals aged 21 years or older who presented to any of the sites for voluntary screening (hereafter, non-hospitalized) and symptomatic inpatients admitted to one of the six treatment centers for the management of COVID-19 (hereafter, hospitalized) were included.",NA,"All","2020-06-15","2020-08-15","Multiple populations","Multiple groups",999,0.32,0.27,0.35,"Convenience","2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo)","Innovita Biological Technology Co. Ltd","LFIA","['IgG', 'IgM']",NA,NA,NA,NA,"https://dx.doi.org/10.1016/j.sciaf.2021.e00802","No representation"
"Colombia","Nelson Alvis Guzma","Using serological studies to assess COVID-19 infection fatality rate in developing countries. A case study from one Colombian department.","Regional","Journal Article (Peer-Reviewed)","Cordoba",NA,">9 years old",NA,"All","2020-03-15","2020-10-02","Household and community samples","Multiple groups",2447,0.408,NA,NA,"Stratified probability","INgezim COVID 19 DR","Eurofins Ingenasa","ELISA","['IgA', 'IgG', 'IgM']","Nucleocapsid(N-protein)","Validated by manufacturers",0.93,0.95,"https://dx.doi.org/10.1016/j.ijid.2021.06.018","No representation"
"Colombia","Evelin Garay","SARS-CoV-2 in eight municipalities of the Colombian tropics: high immunity, clinical and sociodemographic outcomes.","Regional","Journal Article (Peer-Reviewed)","Cordoba Department",NA,"Eight municipalities with the largest populations were chosen between July and November 2020; blood samples were taken from people distributed proportionally from the total population of the eight selected municipalities",NA,"All","2020-07-15","2020-11-15","Household and community samples","Multiple groups",2564,0.408,NA,NA,"Stratified non-probability","INgezim COVID 19 DR","Eurofins Ingenasa","ELISA","['IgA', 'IgG', 'IgM']","Nucleocapsid(N-protein)","Validated by developers",NA,NA,"https://dx.doi.org/10.1093/trstmh/trab094","Included"
"Czechia","Ladislav Dušek","Studie SARS-CoV-2-CZ-Preval","Regional","Presentation or Conference","Brno / South Moravian",NA,"Age from 18 to 89 years
Age from 8 to 17 years (only areas of the capital city of Prague and Brno and its surroundings)
No acute health problems typical of COVID-19
No elevated temperature
No confirmed diagnosis of COVID-19
Permanent / temporary residence in the Czech Republic",NA,"All","2020-04-23","2020-05-01","Household and community samples","Multiple groups",5049,8e-04,1e-04,0.00153,"Stratified non-probability","Coronavirus Antibody Rapid Test","Fortress Diagnostics","LFIA",NA,NA,"Validated by manufacturers",0.95,1,"https://covid-imunita.uzis.cz/res/file/prezentace/20200506-dusek.pdf","No english"
"Faroe Islands","Maria Skaalum Petersen","Seroprevalence of SARS-CoV-2-Specific Antibodies, Faroe Islands","Regional","Journal Article (Peer-Reviewed)","Faroe Islands",NA,"From the Faroese Population Registry, we randomly sampled 1,500 persons and invited them by letter to a clinical visit at 1 of 6 study sites around the islands mainly during week 18 (April 27–May 1, 2020) independently of previous positive PCR test result.",NA,"All","2020-04-27","2020-05-01","Household and community samples","Adults (18-64 years)",1075,0.00699999999999999,NA,NA,"Simplified probability","Wantai SARS-CoV-2 Total Ab ELISA","Beijing Wantai Biological","ELISA","['IgG', 'IgM']","Spike","Validated by manufacturers",0.944,1,"http://dx.doi.org/10.3201/eid2611.202736","No phi_c"
"Germany","Burkhard Tonshoff","Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany.","Regional","Journal Article (Peer-Reviewed)","Baden-Württemberg","Freiburg, Heidelberg, Tübingen, Ulm","Participants were eligible for enrollment if they met the fol- lowing inclusion criteria: (1) 1 child (male or female) aged 1 to 10 years, (2) 1 corresponding parent (male or female) without an age limit (the parents decided among themselves who would participate), (3) residency of the child and parent in the same household, (4) residency in the state of Baden-Württemberg, and (5) written consent to the study.","Key exclusion criteria were (1) severe congenital disease (eg, infantile cerebral palsy, severe congenital malformation), (2) congenital or acquired immunodeficiency, and (3) laboratory-confirmed SARS-CoV-2 infection in the child or participating parent before study enrollment.","All","2020-04-22","2020-05-15","Household and community samples","Adults (18-64 years)",2482,0.019,NA,NA,"Self-referral","Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N),Author designed (Luminex),Author designed (IFA) - Unknown","EUROIMMUN,Roche Diagnostics,NA","Multiple Types","IgG","['Nucleocapsid(N-protein)', 'Spike']","Multiple tests with diff validations or values derived from each type",NA,0.996,"https://dx.doi.org/10.1001/jamapediatrics.2021.0001","No representation"
"Germany","Insa Backhaus","SARS-CoV-2 seroprevalence and determinants of infection in young adults: a population-based seroepidemiological study.","Regional","Journal Article (Peer-Reviewed)","North Rhine-Westphalia","Dusseldorf","All individuals aged 18-30 years who were registered in Düsseldorf in October 2020",NA,"All","2020-11-02","2020-11-27","Household and community samples","Adults (18-64 years)",2186,0.031,0.024,0.04,"Simplified probability","Elecsys® Anti‐SARS‐CoV‐2 (N)","Roche Diagnostics","CLIA","['IgA', 'IgG', 'IgM']","Nucleocapsid(N-protein)","Validated by manufacturers",0.995,0.998,"https://dx.doi.org/10.1016/j.puhe.2022.03.009","No representation"
"Germany","Stefan Lohse","German federal-state-wide seroprevalence study of 1st SARS-CoV-2 pandemic wave shows importance of long-term antibody test performance.","Regional","Journal Article (Peer-Reviewed)","Saarland",NA,"10,000 inhabitants aged 18 years or older representative for the Saarland population with respect to age, sex and location were sampled",NA,"All","2020-07-22","2020-10-15","Household and community samples","Multiple groups",2940,0.0032,NA,NA,"Simplified probability","Anti-SARS-CoV-2 ELISA IgG","EUROIMMUN","ELISA","IgG","Spike","Validated by independent authors/third party/non-developers",0.849,0.993,"https://dx.doi.org/10.1038/s43856-022-00100-z","No asymptomatics"
"Germany","Sebastian Einhauser","Time Trend in SARS-CoV-2 Seropositivity, Surveillance Detection- and Infection Fatality Ratio until Spring 2021 in the Tirschenreuth County-Results from a Population-Based Longitudinal Study in Germany","Regional","Journal Article (Peer-Reviewed)","Tirschenreuth District",NA,"""4203 randomly selected inhabitants of Tirschenreuth aged 14 years or older participated in the baseline survey of the TiKoCo study (response rate: 64.3%)""",NA,"All","2020-06-01","2020-06-30","Household and community samples","Multiple groups",4181,0.0895,NA,NA,"Convenience","Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)","Roche Diagnostics","CLIA","TotalAntibody","['Nucleocapsid(N-protein)', 'Spike']",NA,NA,NA,"https://dx.doi.org/10.3390/v14061168","No asymptomatics"
"Germany","Felix Gunther","Higher Infection Risk among Health Care Workers and Lower Risk among Smokers Persistent across SARS-CoV-2 Waves-Longitudinal Results from the Population-Based TiKoCo Seroprevalence Study.","Regional","Journal Article (Peer-Reviewed)","Bavaria",NA,"""at least 14 years living in the Tirschenreuth county, Germany, """,NA,"All","2020-06-28","2020-07-13","Household and community samples","Multiple groups",4181,0.089,NA,NA,"Simplified probability","Elecsys® Anti‐SARS‐CoV‐2 (N),Elecsys® Anti‐SARS‐CoV‐2 (S)","Roche Diagnostics","CLIA, CMIA,CLIA, CMIA","IgG, IgM, IgA","['Nucleocapsid (N-protein)', 'Spike']",NA,NA,NA,"https://dx.doi.org/10.3390/ijerph192416996","No representation"
"Indonesia","Ni Luh Ayu Megasari","Seroepidemiological
  study of SARS-CoV-2 infection in East Java, Indonesia","Regional","Journal Article (Peer-Reviewed)","East Java","Surabaya, Jombang","""The inclusion criteria were workers (medical personnel, laboratory technician and other staff) and non-COVID-19 patients in medical facilities as well as general population in the community.""","The exclusion criterion was persons less than 16 years old","All","2020-06-15","2020-12-15","Household and community samples","Multiple groups",1819,0.114,NA,NA,"Convenience","2019-Novel Coronavirus (2019-nCoV) IgG/IgM Detection Kit","Nanjing Vazyme Medical Technology Co. Ltd","LFIA","IgG",NA,"Validated by manufacturers",0.9154,0.9702,"https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0251234","No asymptomatics"
"Indonesia","Anak A. S. Sawitri","Seroprevalence of SARS-CoV-2 antibodies in Bali Province: Indonesia shows underdetection of COVID-19 cases by routine surveillance.","Regional","Journal Article (Peer-Reviewed)","Bali",NA,"Cross-sectional sero-surveys were conducted in two rounds between 14 October– 24
December 2020. Specimen collection for round 1 occurred from 14 October– 14 November
and for round 2 from 15 November– 24 December. Urban (Denpasar) compared to rural (outside
Denpasar) stratification was done.

A household was defined as a group of persons who reside in the same place and prepare meals together. All members of selected households who were >= 1 year of age were eligible if informed consent was obtained by either the participant of the parent or guardian.","Samples that did not pass quality check were excluded from the analysis.","All","2020-10-14","2020-11-14","Household and community samples","Multiple groups",1154,0.1804,0.0998,0.261,"Stratified probability","Author designed (Luminex)",NA,"Luminex","IgG","['Nucleocapsid(N-protein)', 'Spike']",NA,NA,NA,"https://dx.doi.org/10.1371/journal.pgph.0000727","No representation"
"Iran","Maryam Shakiba","Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020","Regional","Journal Article (Peer-Reviewed)","Guilan",NA,"All persons living in a household, regardless of age, were invited through multistage cluster random sampling",NA,"All","2020-04-11","2020-04-19","Household and community samples","Multiple groups",528,0.222,0.164,0.285,"Stratified probability","VivaDiag COVID-19 IgM/IgG Rapid Test","VivaChek Biotech (Hangzhou) Co. Ltd","LFIA","['IgG', 'IgM']",NA,"Validated by independent authors/third party/non-developers",0.833,0.99,"https://dx.doi.org/10.3201/eid2702.201960","Included"
"Iran","Seyed Abbas Mousavi","Seroprevalence of SARS-CoV-2 in Mazandaran province, Iran","Regional","Journal Article (Peer-Reviewed)","Mazandaran",NA,"all the household members older than seven years old were the population of our study","The exclusion criteria were: (1) living in retirement homes, prisons, or boarding schools, (2) being intolerant for disinfectants, (3) being in the treatment process of COVID-19, and (4) not cooperating until the end of the study.","All","2020-03-15","2020-05-15","Household and community samples","Multiple groups",1588,0.1729,0.1484,0.1779,"Stratified probability","ELISA kit Pishtaz Teb Diagnostics","Pishtaz Diagnostics Iran","ELISA","['IgG', 'IgM']",NA,"Validated by independent authors/third party/non-developers",0.59,1,"https://www.apjtm.org/article.asp?issn=1995-7645;year=2021;volume=14;issue=1;spage=10;epage=16;aulast=Mousavi","No phi_c"
"Iran","Fatemeh Khosravi Shadmani","Seroprevalence of SARS-Cov-2 Virus Infection In Kermanshah, Iran: A Population-based Cross-Sectional Study","Regional","Journal Article (Peer-Reviewed)","Kermanshah",NA,"All individuals from the prespecified location were brought into the study regardless of previous COVID-19 infection history.","The exclusion criterion consisted of the unwillingness to participate in the study, inability to answer the questions, and residence in that area for
less than a year.","All","2020-11-15","2020-12-20","Household and community samples","Multiple groups",1967,0.202,NA,NA,"Stratified probability","ELISA kit Pishtaz Teb Diagnostics","Pishtaz Diagnostics Iran","ELISA","['IgG', 'IgM']",NA,"Validated by manufacturers",0.941,0.983,"https://dx.doi.org/10.2174/18749445-v16-230303-2022-92","No representation"
"Italy","Angelo Amante","Over half of people tested in Italy's  Bergamo have COVID-19 antibodies","Regional","News and Media","Lombardy",NA,"Residents in Bergamo",NA,"All","2020-04-23","2020-06-03","Household and community samples","Multiple groups",9965,0.57,NA,NA,"Simplified probability","Not reported/ Unable to specify",NA,NA,NA,NA,NA,NA,NA,"https://www.google.com/url?rct=j&sa=t&url=https://www.thejakartapost.com/news/2020/06/09/over-half-of-people-tested-in-italys-bergamo-have-covid-19-antibodies.html&ct=ga&cd=CAAYAjIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNEF-NEDdVnSHZTUUTQEQL5px8dXmw","News article"
"Italy","Paola Stefanelli","Prevalence of SARS-CoV-2 IgG antibodies in an area of North-eastern Italy with a high incidence of COVID-19 cases: a population-based study.","Regional","Journal Article (Peer-Reviewed)","Trento",NA,"All citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases","Individuals with severe disease or who were institutionalized in nursing homes were excluded.","All","2020-05-05","2020-05-15","Household and community samples","Multiple groups",6075,0.257,NA,NA,"Convenience","Abbott Architect SARS-CoV-2 IgG","Abbott Laboratories","CLIA","IgG","Nucleocapsid(N-protein)","Validated by manufacturers",0.9,1,"https://dx.doi.org/10.1016/j.cmi.2020.11.013","No representation"
"Italy","Vieri Lastrucci","SARS-CoV-2 Seroprevalence Survey in People Involved in Different Essential Activities during the General Lock-Down Phase in the Province of Prato (Tuscany, Italy)","Regional","Journal Article (Peer-Reviewed)","Prato",NA,"The study sample wascomposed of people aged 18 years or older involved in different activities considered essential duringthe lock-down period. In particular, the following population groups were invited to participate in thestudy: workers of the Local Health Authority (LHA), workers and volunteers of the Civil Protection,and public employees of the Province of Prato and of the municipalities of Cantagallo, Carmignano,Montemurlo, Poggio a Caiano, Vaiano, and Vernio.  All the people belonging to these populationgroups in the Province of Prato were invited to participate",NA,"All","2020-05-01","2020-05-31","Multiple populations","Multiple groups",4656,0.03,0.025,0.035,"Convenience","LYHER Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit(Colloidal Gold)","Hangzhou Laihe Biotech Co. Ltd","LFIA","['IgG', 'IgM']",NA,"Validated by independent authors/third party/non-developers",1,0.988,"https://dx.doi.org/10.3390/vaccines8040778","No representation"
"Italy","Omar Nyabi","Diagnostic value of igm and igg detection in covid-19 diagnosis by the mobile laboratory b-life: A massive testing strategy in the piedmont region","Regional","Journal Article (Peer-Reviewed)","PIedmont",NA,"regional civil protection (CP), police, healthcare personnel, and volunteers working in the COVID pandemic phase",NA,"All","2020-06-20","2020-07-23","Multiple populations","Multiple groups",6033,0.048,NA,NA,"Convenience","QuickZen® COVID-19 IgM/IgG kit","ZenTech, Angleur, Belgium","LFIA","['IgG', 'IgM']","Spike","Validated by manufacturers",NA,NA,"http://dx.doi.org/10.3390/ijerph18073372","No representation"
"Italy","Francesco Napolitano","Seroprevalence
  of SARS-CoV-2 Antibodies in Adults and Healthcare Workers in Southern Italy","Regional","Journal Article (Peer-Reviewed)","Southern Italy","Caserta, Naples","The study population consisted of participants: (1) who were in contact with patients such as HCWs and medical students; (2) who were not in contact with patients, but with HCWs,
such as technicians, laboratory assistants, custodians, cleaners, and administrative staff of the Teaching Hospital; (3) non-medical students, faculty members, research fellows and
administrative staff of non-medical University Departments.",NA,"All","2020-09-21","2020-12-31","Multiple populations","Multiple groups",2394,0.0585,NA,NA,"Convenience","VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,Liaison SARS-CoV-2 S1/S2 IgG","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,DiaSorin","CLIA","TotalAntibody",NA,"Validated by manufacturers",NA,NA,"https://www.mdpi.com/1660-4601/18/9/4761","No representation"
"Japan","Morihito Takita","Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic–Based Point-of-Care Antibody Testing","Regional","Journal Article (Peer-Reviewed)","Kantō, Chūbu","Tokyo, Kangawa, Saitama, Chiba, Yamanashi","subjects have been recruited by web posting of clinics. The two community clinics located in the major railway stations in Tokyo (Navitas Clinic Shinjuku and Tachikawa)","Symptomatic patients","All","2020-04-20","2020-05-20","Household and community samples","Multiple groups",1071,0.0383,0.0276,0.0516,"Self-referral","SARS-CoV-2 antibody detection kit (IgM/IgG)","Kurabo Industries Ltd","LFIA","IgG",NA,"Validated by manufacturers",0.764,1,"https://dx.doi.org/10.1177/2150132720942695","No representation"
"Japan","Nobutoshi Nawa","Seroprevalence of SARS‐CoV‐2 in Utsunomiya City, Greater Tokyo, after the first pandemic in 2020","Regional","Journal Article (Peer-Reviewed)","Tochigi Prefecture","Utsunomiya City","households in Utsunomiya City, Tochigi Prefecture, Greater Tokyo, Japan.",NA,"All","2020-06-14","2020-07-05","Household and community samples","Multiple groups",742,0.0123,0.0017,0.0228,"Simplified probability","iFlash-SARS-CoV-2 IgM/IgG","Shenzhen Yhlo Biotech Co. Ltd","CLIA","IgG",NA,"Validated by manufacturers",0.973,0.963,"https://onlinelibrary.wiley.com/doi/full/10.1002/jgf2.408","No asymptomatics"
"Japan","Prefecture of Hiroshima","About the result of the 2nd new coronavirus antibody prevalence survey","Regional","Institutional Report","Hiroshima Prefecture","Hiroshima, Fukuyama, Miyoshi, and Higashi-Hiroshima","Residents of 5 municipalities (Hiroshima City, Fukuyama City, Miyoshi City, Higashi Hiroshima City and Kitahiroshima Town) of Hiroshima Prefecture",NA,"All","2020-10-15","2020-11-15","Household and community samples","Multiple groups",2396,0.0025,NA,NA,"Simplified probability","Elecsys® Anti‐SARS‐CoV‐2 (N)","Roche Diagnostics","CLIA",NA,NA,NA,NA,NA,"https://www.chugoku-np.co.jp/local/news/article.php?comment_id=726622&comment_sub_id=0&category_id=256","Institute report"
"Japan","The Bharat Express News","1.35% in Tokyo have antibodies against the coronavirus","Regional","News and Media","Aichi Prefecture",NA,NA,NA,"All","2020-12-14","2020-12-26","Household and community samples","Multiple groups",2960,0.00709999999999999,NA,NA,"Unclear","Not reported/ Unable to specify",NA,NA,NA,NA,NA,NA,NA,"https://www.thebharatexpressnews.com/1-35-in-tokyo-have-antibodies-against-the-coronavirus/","News article"
"Japan","Akihisa Mitani","Epidemiological study using IgM and IgG antibody titers against SARS-CoV-2 in The University of Tokyo, Japan (UT-CATS).","Regional","Journal Article (Peer-Reviewed)",NA,"Tokyo","students, staff, and faculty members of The University of Tokyo from June 2020 to October 2020",NA,"All","2020-06-11","2020-10-28","Multiple populations","Multiple groups",6609,0.0048,NA,NA,"Self-referral","iFlash-SARS-CoV-2 IgM/IgG","Shenzhen Yhlo Biotech Co. Ltd","CLIA","IgG","['Nucleocapsid(N-protein)', 'Spike']","Validated by independent authors/third party/non-developers",NA,NA,"https://dx.doi.org/10.1016/j.jiac.2021.06.008","No representation"
"Japan","Akihisa Mitani","Interpretations of SARS-CoV-2 IgM and IgG antibody titers in the seroepidemiological study of asymptomatic healthy volunteers.","Regional","Journal Article (Peer-Reviewed)",NA,"Tokyo","asymptomatic subjects among students, staff, and faculty members of the University of Tokyo, Japan

All participants were 18 years or older.",NA,"All","2020-06-11","2020-12-22","Multiple populations","Adults (18-64 years)",10039,0.0023,NA,NA,"Convenience","iFlash-SARS-CoV-2 IgM/IgG","Shenzhen Yhlo Biotech Co. Ltd","CLIA","IgG","['Nucleocapsid(N-protein)', 'Spike']",NA,NA,NA,"https://dx.doi.org/10.1016/j.jiac.2021.11.020","No representation"
"Jersey","Statistics Jersey","SARS-CoV-2: Prevalence of antibodies in Jersey - Preliminary Analysis","Regional","Institutional Report","Jersey",NA,"A list of 700 private addresses were randomly drawn from the Jersey Land and Property Register (JLPR) which formed the basis of the sample for this study; in respect of the adult resident population living in private households","The sample drawn excluded communal establishments (such as care homes), commercial properties and a small number of other properties known not to be residential in nature.

The survey did not perform testing on anyone aged under 16 years and did not include residents of communal establishments (such as care homes).","All","2020-04-29","2020-05-05","Household and community samples","Multiple groups",855,0.031,0.018,0.044,"Stratified probability","COVID-19 IgG/IgM Rapid Test Cassette","Healgen","LFIA","['IgG', 'IgM']",NA,NA,0.833,1,"https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%202020508%20SJ.pdf","Institute report"
"Jersey","Statistics Jersey","SARS-CoV-2: Prevalence of antibodies in Jersey - Community survey – round 2","Regional","Institutional Report","Jersey",NA,"Adult residents living in private households, above the age of 16.","Under 16 years, or residents of communal establishments, such as care homes.","All","2020-05-15","2020-05-27","Household and community samples","Multiple groups",1062,0.042,0.029,0.055,"Stratified probability","OnSite COVID-19 IgG/IgM Rapid Test","CTK Biotech, Inc.","LFIA","['IgG', 'IgM']",NA,"Multiple tests with diff validations or values derived from each type",0.9,0.9939,"https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%2020200609%20SJ.pdf","Institute report"
"Nigeria","OgoChukwu Vincent Okpala","Population seroprevalence of SARS-CoV-2 antibodies in Anambra state, South-East, Nigeria","Regional","Journal Article (Peer-Reviewed)","Anambra State",NA,"For each selected health facility , all clients (≥ one year of age) and health staff were eligible for the survey.","Clients and staff that declined consent were excluded from the study.","All","2020-12-08","2020-12-15","Household and community samples","Multiple groups",3142,0.1607,NA,NA,"Stratified probability","Realy-Tech 2019 nCOV/COVID-19 IgG/IgM Rapid Test","Hangzhou Realy Tech Co. Ltd","LFIA","['IgG', 'IgM']",NA,"Validated by manufacturers",0.98,0.99,"https://www.sciencedirect.com/science/article/pii/S1201971221005968","Included"
"Pakistan","Wajiha Javed","Sero-prevalence findings from metropoles in Pakistan: implications for assessing COVID-19 prevalence and case-fatality within a dense, urban working population","Regional","Preprint",NA,"Karachi, Lahore, Multan, Peshawar and Quetta","adult, working population aged 18-65 years, recruited from dense, urban workplaces including
factories, corporates, restaurants, media houses, schools, banks, healthcare providers in hospitals, and families
of positive cases in various metropoles of Pakistan",NA,"All","2020-07-06","2020-07-06","Household and community samples","Adults (18-64 years)",24210,0.175,NA,NA,"Simplified probability","IgG/IgM Test Kit (Colloidal gold)","Getz Pharma","LFIA","['IgG', 'IgM']",NA,"Validated by independent authors/third party/non-developers",NA,NA,"https://www.medrxiv.org/content/10.1101/2020.08.13.20173914v1","No representation"
"Pakistan","Muhammad Imran Nisar","Community-based seroprevalence of SARS CoV-2 in an urban district of Karachi, Pakistan","Regional","Journal Article (Peer-Reviewed)","Karachi",NA,"All household members were eligible to participate regardless of age and infection status in the District East of Karachi",NA,"All","2020-11-01","2020-11-30","Household and community samples","Multiple groups",500,0.24,0.18,0.31,"Simplified probability","Elecsys® Anti‐SARS‐CoV‐2 (Type Unknown)","Roche Diagnostics","CLIA","['IgG', 'IgM']",NA,NA,NA,NA,"https://www.joghr.org/article/84241-community-based-seroprevalence-of-sars-cov-2-in-an-urban-district-of-karachi-pakistan","Better study available"
"Peru","Cristian Diaz Velez","SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June-July 2020","Regional","Journal Article (Peer-Reviewed)","Lambayeque Province",NA,"Population of the Lambayeque region","People who had previously had a diagnosis of SARS-CoV-2 by RT-PCR or by serological test are excluded","All","2020-06-24","2020-07-10","Household and community samples","Multiple groups",2010,0.295,0.276,0.315,"Stratified probability","Coretests COVID-19 IgM/IgG Ab Test","Core Technology Co. Ltd","LFIA","['IgG', 'IgM']",NA,"Validated by independent authors/third party/non-developers",0.66,0.97,"https://dx.doi.org/10.7717/peerj.11210","Included"
"Peru","Charles Huamani","SARS-CoV-2 seroprevalence in a high-altitude setting in Peru: Adult population-based cross-sectional study","Regional","Journal Article (Peer-Reviewed)","Cusco Region",NA,"""People aged≥18 years old, who voluntarily agreed to participate in the study, signed theirinformed consent, accepted the telephone and serological follow-up, usual resident of thestudy area (≥6 months), and with the ability to understand the procedures were included.""

""We did not exclude people with acute symptoms or who had already given positive results to previous tests.""",NA,"All","2020-09-12","2020-09-27","Household and community samples","Multiple groups",1924,0.331,0.301,0.364,"Simplified probability","Elecsys® Anti‐SARS‐CoV‐2 (N)","Roche Diagnostics","CLIA","TotalAntibody","Nucleocapsid(N-protein)","Validated by independent authors/third party/non-developers",0.967,0.986,"http://dx.doi.org/10.7717/peerj.12149","Better study available"
"Poland","Małgorzata Kowalska","Association between Influenza Vaccination and Positive SARS-CoV-2 IgG and IgM Tests in the General Population of Katowice Region, Poland.","Regional","Journal Article (Peer-Reviewed)","Silesian Voivodeship","Katowice, Gliwice, Sosnowiec","General population in the Silesian Voivodeship (Katowice, Gliwice, and Sosnowiec) with records at the central statistical office in Poland",NA,"All","2020-10-15","2020-11-15","Household and community samples","Multiple groups",5479,0.229,NA,NA,"Self-referral","Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA","EUROIMMUN","ELISA","IgG","Spike",NA,NA,NA,"https://dx.doi.org/10.3390/vaccines9050415","No asymptomatics"
"Russian Federation","Anna Popova","Assessment of the Herd Immunity to SARS-CoV-2 among the Population of the Leningrad Region during the COVID-19 Epidemic","Regional","Journal Article (Peer-Reviewed)","Northwestern Federal District",NA,"Members of the Leningrad general population","Active COVID-19 infection","All","2020-06-23","2020-06-26","Household and community samples","Multiple groups",3130,0.207,NA,NA,"Simplified probability","Author designed (ELISA) - Nucleocapsid",NA,"ELISA","IgG","Nucleocapsid(N-protein)",NA,NA,NA,"https://journal.microbe.ru/jour/article/view/1371/1150#","No english"
"Russian Federation","Anna Popova","Distribution of SARS-CоV-2 seroprevalence among residents of the Tyumen Region during the COVID-19 epidemic period","Regional","Journal Article (Peer-Reviewed)","Tyumen region",NA,"Volunteers for participation in the study were selected through questionnaire surveys and random sampling","The exclusion criterion was an active COVID-19 infection at the time of the survey.","All","2020-06-07","2020-06-20","Household and community samples","Multiple groups",2758,0.245,0.229,0.261,"Simplified probability","Author designed (ELISA) - Nucleocapsid",NA,"ELISA","IgG","Nucleocapsid(N-protein)",NA,NA,NA,"https://microbiol.elpub.ru/jour/article/view/890/520","No english"
"Russian Federation","Anna Popova","Experience in Studying Seroprevalence to SARS-CoV-2 Virus in the Population of the Irkutsk Region during COVID-19 Outbreak","Regional","Journal Article (Peer-Reviewed)","Irkutsk Region",NA,NA,"The exclusion criterion is active COVID-19 infection at the time of the questionnaire.","All","2020-06-28","2020-07-19","Household and community samples","Multiple groups",2674,0.058,0.0535,0.0625,"Simplified probability","Author designed (ELISA) -Unknown",NA,"ELISA","IgG",NA,NA,NA,NA,"https://journal.microbe.ru/jour/article/view/1370/1149","No english"
"Russian Federation","A Popova","The structure of seroprevalence to the SARS-COV-2 virus among residents of the Moscow region during the period of epidemic incidence of COVID-19","Regional","Journal Article (Peer-Reviewed)","Central Russia","Moscow Region",NA,"exclusion criteria: there was an active COVID-19 infection at the time of the questionnaire rationing","All","2020-06-22","2020-07-11","Household and community samples","Multiple groups",2688,0.21,NA,NA,"Simplified probability","ELISA anti-SARS-CoV reagent kit -2 IgG","FBSI State scientific center for applied microbiology and biotechnology","ELISA","IgG","Nucleocapsid(N-protein)",NA,NA,NA,"http://dx.doi.org/10.20953/1729-9225-2020-4-17-26","No english"
"Russian Federation","Anna Yu Popova","Distribution of SARS-CоV-2 seroprevalence among residents of the Republic of Tatarstan during the COVID-19 epidemic period","Regional","Journal Article (Peer-Reviewed)","Republic of Tartarstan",NA,"population of the Republic of Tatarstan","The exclusion criterion was active COVID-19 infection at the time of the survey.","All","2020-09-20","2020-09-27","Household and community samples","Multiple groups",2946,0.313,NA,NA,"Simplified probability","Not reported/ Unable to specify",NA,"ELISA","IgG","Nucleocapsid(N-protein)",NA,NA,NA,"https://microbiol.elpub.ru/jour/article/view/940?locale=en_US","No english"
"Russian Federation","Anna Popova","Humoral immunity to SARS-CoV-2 in the population of the Murmansk region against the background of the incidence of COVID-19","Regional","Journal Article (Peer-Reviewed)","Murmansk Region",NA,NA,"Active COVID-19 infection at the time of the survey","All","2020-08-03","2020-08-11","Household and community samples","Multiple groups",3117,0.312,0.304,0.32,"Stratified probability","ELISA anti-SARS-CoV reagent kit -2 IgG","FBSI State scientific center for applied microbiology and biotechnology","ELISA","IgG","Nucleocapsid(N-protein)",NA,NA,NA,"https://hiv.bmoc-spb.ru/jour/article/view/605#","No english"
"Russian Federation","A Yu Popova","Herd immunity of sars-CoV-2 among the population of Kalinigrad region amid the COVID-19 epidemic","Regional","Journal Article (Peer-Reviewed)","Kaliningrad Region",NA,"Individuals in Kaliningrad, Russia","The exclusion criterion was active COVID-19 infection at the time of the survey.","All","2020-08-03","2020-08-07","Household and community samples","Multiple groups",2939,0.502,0.4903,0.511,"Stratified probability","ELISA anti-SARS-CoV reagent kit -2 IgG","FBSI State scientific center for applied microbiology and biotechnology","ELISA","IgG","Nucleocapsid(N-protein)",NA,NA,NA,"http://dx.doi.org/10.22625/2072-6732-2020-12-5-62-71","No english"
"Russian Federation","A Papova","Characteristic of herd immunity among the population of Stavropol region amid the COVID-19 epidemic","Regional","Journal Article (Peer-Reviewed)","Stavropol Region",NA,NA,"The exclusion criterion was active COVID-19 infection at the time of the questionnaire.","All","2020-06-06","2020-06-29","Household and community samples","Multiple groups",2683,0.098,0.087,0.109,"Convenience","Author designed (ELISA) - Unknown",NA,"ELISA","IgG","Nucleocapsid(N-protein)",NA,NA,NA,"https://dx.doi.org/10.22625/2072-6732-2021-13-4-79-89","No english"
"Saudi Arabia","Abdulaziz Alhazmi","Community-based seroprevalence of sars-cov-2 antibodies following the first wave of the covid-19 pandemic in jazan province, saudi arabia","Regional","Journal Article (Peer-Reviewed)","Jazan province",NA,"Individuals from all age groups were
included and gave informed consent to information that was provided to all participants,
or their legal guardians, before they were enrolled in the study.","Participants who refused to participate, pregnant women, and patients
with known chronic immunological diseases were excluded from this study.","All","2020-08-25","2020-12-30","Household and community samples","Multiple groups",594,0.2575,0.212,0.3,"Self-referral","COVID-19 ELISA IgG,Author designed (ELISA) -Spike","Vircell S.L.,NA","ELISA","IgG","['Nucleocapsid(N-protein)', 'Spike']",NA,NA,NA,"http://dx.doi.org/10.3390/ijerph182312451","No asymptomatics"
"Serbia","Mioljub Ristic","Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.","Regional","Journal Article (Peer-Reviewed)","Vojvodina",NA,"135 sentinel physicians (general practitioners and pediatricians) were involved at primary (outpatient) medical care sites, across 44 settlements in Vojvodina, recruited a representative sample of their patients on a voluntary basis. only two healthy participants per family were included.","Only respondents without any COVID-19-related symptoms within 30 days and without known direct contact with laboratory-confirmed COVID-19 case in the past 14 days were invited to participate in the study by their sentinel physicians.","All","2020-04-17","2020-04-30","Household and community samples","Multiple groups",1267,0.026,0.018,0.0363,"Stratified probability","2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo)","Innovita Biological Technology Co. Ltd","LFIA","['IgG', 'IgM']",NA,"Validated by independent authors/third party/non-developers",0.873,1,"https://dx.doi.org/10.1371/journal.pone.0254516","No asymptomatics"
"South Africa","Hannah Hussey","Epidemiology and outcomes of SARS-CoV-2 infection associated with anti-nucleocapsid seropositivity in Cape Town, South Africa","Regional","Preprint","Western Cape","Cape Town",NA,NA,"All","2020-08-17","2020-11-06","Multiple general populations","Multiple groups",2327,0.3919209282,0.3723,0.4119,"Convenience","Elecsys® Anti‐SARS‐CoV‐2 (N)","Roche Diagnostics","CLIA","['IgA', 'IgG', 'IgM']","Nucleocapsid(N-protein)","Validated by independent authors/third party/non-developers",0.89,1,"10.1101/2022.12.01.22282927","Preprint"
"Sudan","William McCollum","Sudan FETP Conducts Targeted Testing for COVID-19 in Khartoum State","Regional","News and Media","Khartoum",NA,NA,NA,"All","2020-05-22","2020-07-05","Household and community samples","Multiple groups",967,0.183,NA,NA,"Unclear","Not reported/ Unable to specify",NA,"LFIA",NA,NA,NA,NA,NA,"https://www.tephinet.org/sudan-fetp-conducts-targeted-testing-for-covid-19-in-khartoum-state","News article"
"Switzerland","Silvia Stringhini","Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study","Regional","Journal Article (Peer-Reviewed)","Geneva",NA,"Eligible individuals were aged 20–74 years, identified through an annual residential list established by the local government and provided informed consent. Participants only eligible to participate once.","Individuals who were permanent residents of institutions (eg, prisons and care homes) were excluded.","All","2020-04-06","2020-05-09","Household and community samples","Multiple groups",2766,0.0781,NA,NA,"Stratified probability","Anti-SARS-CoV-2 ELISA IgG","EUROIMMUN","ELISA","IgG","Spike","Validated by independent authors/third party/non-developers",0.93,NA,"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31304-0/fulltext#seccestitle10","No phi_c"
"Switzerland","Aude Richard","Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study","Regional","Journal Article (Peer-Reviewed)","Canton of Geneva",NA,"SEROCoV-POP is a population-based repeated cross-sectional observational seroprevalence study. We recruited participants between 6 April and 30 June 2020. The recruitment strategy and serological data collection have previously been described in detail [4]. Briefly, participants were invited progressively by email and postal mail from the study population of a yearly health survey called Bus Santé [19], which is representative of the 20–74-year-old population of canton Geneva. Participants were invited to bring members of their household aged 5 years and older.",NA,"All","2020-04-06","2020-06-30","Household and community samples","Multiple groups",8344,0.078,0.068,0.089,"Simplified probability","Anti-SARS-CoV-2 ELISA IgG","EUROIMMUN","ELISA","IgG","Spike","Validated by independent authors/third party/non-developers",0.93,1,"https://www.medrxiv.org/content/10.1101/2020.12.16.20248180v1.full-text","Included"
"Switzerland","Ottavio Beretta","Seroprevalence of the SARS-CoV-2 virus in the population of the southern Switzerland (Canton Ticino) - cohort study, results at 12 months.","Regional","Journal Article (Peer-Reviewed)","Ticino",NA,"1500 persons from the Civil Registry Office database. The
sample was representative of the general population of the
Canton of Ticino, stratified by sex and age from 5 years
old.","Aged younger than 5 years old","All","2020-05-11","2020-06-28","Household and community samples","Multiple groups",934,0.09,0.071,0.112,"Stratified probability","Rapid Test SARS-CoV-2 IgM/IgG Gold","Technogenetics","LFIA","['IgG', 'IgM']","Nucleocapsid(N-protein)","Validated by manufacturers",0.951,0.989,"https://smw.ch/article/doi/smw.2021.w30116","No phi_c"
"Switzerland","Agne Ulyte","SARS-CoV-2 seroprevalence in children, parents and school personnel from June 2020 to April 2021: cohort study of 55 schools in Switzerland","Regional","Preprint","Zurich",NA,"""Within participating schools, children from randomly
selected classes, all school personnel and parents of participating children were invited.""","""We excluded vaccinated adults (n=123) and those eligible for vaccination but with unclear vaccination status (n=215) from the main analysis.""","All","2020-08-15","2020-09-15","Household and community samples","Multiple groups",2045,0.058,0.035,0.078,"Convenience","Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological (SenASTrIS)","Swiss Federal Institute of Technology",NA,NA,"Spike","Validated by independent authors/third party/non-developers",0.983,0.984,"https://www.medrxiv.org/content/10.1101/2022.01.25.22269827v1.full-text","No representation"
"Switzerland","Hugo-Alejandro Santa-Ramirez","Socio-economic determinants of SARS-CoV-2 infection: Results from a population-based cross-sectional serosurvey in Geneva, Switzerland","Regional","Journal Article (Peer-Reviewed)","Canton of Geneva",NA,"""Data was obtained from a population-based serosurvey of adults in Geneva and their household members"".

""We limited our sample to adults aged 18 years and older"".",NA,"All","2020-11-23","2020-12-23","Household and community samples","Multiple groups",2899,0.2046,NA,NA,"Stratified probability","Elecsys® Anti‐SARS‐CoV‐2 (S)","Roche Diagnostics","CLIA","TotalAntibody","Spike","Validated by manufacturers",0.988,0.9998,"https://dx.doi.org/10.3389/fpubh.2022.874252","No asymptomatics"
"Switzerland","Rebecca Amati","Trajectories of Seroprevalence and Neutralizing Activity of Antibodies against SARS-CoV-2 in Southern Switzerland between July 2020 and July 2021: An Ongoing, Prospective Population-Based Cohort Study.","Regional","Journal Article (Peer-Reviewed)","Ticino Canton",NA,"""Corona Immunitas Ticino” is a population-based cohort study of a representativesample of community-dwelling residents of Ticino (southern Switzerland) aged five years and older""","NR","All","2020-07-15","2020-07-31","Household and community samples","Adults (18-64 years)",646,0.078,0.054,0.104,"Convenience","Author designed (Luminex)",NA,"Luminex","TotalAntibody","['Nucleocapsid(N-protein)', 'Spike']",NA,NA,NA,"https://dx.doi.org/10.3390/ijerph20043703","No asymptomatics"
"Tunisia","Sonia Dhaouadi","Baseline Seroprevalence of SARS-CoV-2 Specific Antibodies in Hot Spot Areas of Great Tunis, up to 3 Months Post Disease Onset in Tunisia.","Regional","Journal Article (Peer-Reviewed)","Great Tunis",NA,"""All persons present at the time of the survey in their household, irrespective of their COVID-19 status including children and have given their informed consent, were asked to participate in the study""","""Subjects who refused to give informed consent or to be sampled, or had any contraindication to capillary puncture were not included in this study.""","All","2020-04-01","2020-04-30","Household and community samples","Multiple groups",1049,0.008,0,0.022,"Convenience","Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography)","Beijing Lepu Medical Technology","LFIA","['IgG', 'IgM']","Nucleocapsid(N-protein)","Validated by independent authors/third party/non-developers",0.657,0.657,"https://dx.doi.org/10.3390/epidemiologia4020020","No representation"
"United Arab Emirates","Ahmed R Alsuwaidi","Seroprevalence of COVID-19 infection in the Emirate of Abu Dhabi, United Arab Emirates: a population-based cross-sectional study","Regional","Journal Article (Peer-Reviewed)","Emirate of Abu Dhabi","Abu Dhabi, Al Ain, Al Dhafra","We separately surveyed cluster samples of households and of labour camps from three regions in the Emirate of Abu Dhabi (Abu Dhabi, Al Ain and Al Dhafra), considering that labour-camp workers exhibit different socio-demographic characteristics compared with the household population.

If a household was unwilling to participate in the study or if the household doorbell was not answered, the next household was selected instead. All residents in the sampled households were invited to participate in the study, irrespective of age or prior COVID-19 infection.","The exclusion criteria included the refusal to provide informed consent or contraindication to venipuncture.","All","2020-07-19","2020-08-14","Household and community samples","Multiple groups",8831,0.104,0.095,0.114,"Stratified probability","Liaison SARS-CoV-2 S1/S2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","DiaSorin,Roche Diagnostics","CLIA","IgG",NA,"Validated by independent authors/third party/non-developers",0.974,0.985,"https://academic.oup.com/ije/advance-article/doi/10.1093/ije/dyab077/6248207","No representation"
"occupied Palestinian territory - including east Jerusalem","I Rayan","Sero Prevalence of COVID-19 in Palestine in 2020","Regional","Preprint","Gaza",NA,"All individuals over the age of 10 years irrespective of known prior COVID-19 infection who resided in the area under study during the period of SARS-CoV-2 transmission and who can give consent, or in the case of minor children, whose legal guardian can give consent for them.","All individuals who refuse or are unable to give informed consent, or who present contraindication to venipuncture. Prisoners were excluded due to logistical difficulties. Individuals with conditions that make sampling them potentially harmful and persons currently infected with COVID-19.","All","2020-12-01","2020-12-31","Household and community samples","Multiple groups",2904,0.4,NA,NA,"Stratified probability","Elecsys® Anti‐SARS‐CoV‐2 (S)","Roche Diagnostics","CLIA","IgG","Spike","Validated by manufacturers",0.988,0.9998,"https://www.medrxiv.org/content/10.1101/2021.10.04.21263131v1","Preprint"
